Fundraising FoxSavara
NASDAQ: SVRAAustin, US · Delaware corporation · 2 known investors
Find your way into Savara
80 people in our graph share verified history with the Savara team — schools, employers, funds. One of them is your warm intro.
Raja Gopalakrishnanunlockedknows Chris Marich · together at Bank of America (overlapped)
×9knows the team · via Bank of America
×2knows the team · via Savara
Savara is a biopharmaceutical company developing product candidates for the treatment of autoimmune pulmonary alveolar proteinosis and related conditions. The company operates as a clinical-stage pharmaceutical developer focused on bringing therapeutic solutions to patients with rare and serious diseases.
Founders & leadership
RN
Robert NevilleFounder
JL
John LordExecutive
CM
Chris MarichExecutiveChris Marich is Executive Officer at Savara, a clinical-stage biopharmaceutical company developing treatments for autoimmune pulmonary alveolar proteinosis and related rare diseases. With over 20 years of experience in life sciences and enterprise software, he has founded and built companies with investor returns and has focused on pharmaceutical product development for unmet medical needs since 2008.
TJ
Taneli JouhikainenExecutive
MP
Matthew PaulsChief Executive Officer; Chair of the Board of Directors
Board
YP
Yuri PikoverBoard director
NE
Nevan ElamBoard director
JS
Joseph S. McCrackenBoard director
RH
Richard HawkinsBoard director
Investors · 2
BlackRockreportedMexico City
How we know: funding news · Not right? Tell us
Also in the syndicate · 1
RTW
Funding
SEC filings, press & company announcements$35.2M disclosed across 3 of 6 rounds · 1900–2025
- Undisclosed amountRoyalty Funding AgreementOct 2025
RTW
Source ↗
▶$5MofferedJul 2016 · PharmaceuticalsRule 506(b)
▶$5MofferedJul 2016 · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Nevan ElamDirector
- Yuri PikoverDirector
- Richard HawkinsDirector
- Joseph S. McCrackenDirector
- Taneli JouhikainenExecutive Officer
- Robert NevilleExecutive Officer, Director
- Mike CieslaExecutive Officer
- John LordExecutive Officer
- Chris MarichExecutive Officer
- Offering amount
- $5M
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$20.7MraisedMar 2016 · 206 investors · PharmaceuticalsRule 506(b)
▶$20.7MraisedMar 2016 · 206 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- John LordExecutive Officer
- Nevan ElamDirector
- Joseph S. McCrackenDirector
- Chris MarichExecutive Officer
- Richard HawkinsDirector
- Robert NevilleExecutive Officer, Director
- Taneli JouhikainenExecutive Officer
- Yuri PikoverDirector
- Offering amount
- $21M
- Amount sold
- $20.7M
- First sale
- Dec 2015
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$10MraisedOct 2014 · 139 investors · PharmaceuticalsRule 506(b)
▶$10MraisedOct 2014 · 139 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Chris MarichExecutive Officer
- Yuri PikoverDirector
- Joe McCrackenDirector
- Robert NevilleExecutive Officer, Director
- Nevan ElamDirector
- Rick HawkinsDirector
- Taneli JouhikainenExecutive Officer
- Offering amount
- $10M
- Amount sold
- $10M
- First sale
- Jun 2014
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$4.5MraisedJun 2014 · 56 investors · PharmaceuticalsRule 506(b)
▶$4.5MraisedJun 2014 · 56 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Yuri PikoverDirector
- Rick HawkinsDirector
- Joe McCrackenDirector
- Robert NevilleExecutive Officer, Director
- Chris MarichExecutive Officer
- Nevan ElamDirector
- Taneli JouhikainenExecutive Officer
- Offering amount
- $5M
- Amount sold
- $4.5M
- First sale
- Jun 2014
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
In the news
How Investors Are Reacting To Savara (SVRA) Wider Q2 Loss And New US$108 Million Share Shelf - Simply Wall St Newssimplywall.st · Aug 2026Frequently asked questions
- What does Savara do?
- Savara is a biopharmaceutical company developing product candidates for the treatment of autoimmune pulmonary alveolar proteinosis and related conditions. The company operates as a clinical-stage pharmaceutical developer focused on bringing therapeutic solutions to patients with rare and serious diseases.
- Who founded Savara?
- Savara was founded by Robert Neville.
- Who are Savara's investors?
- Savara's investors include BlackRock.
- How much funding has Savara raised?
- Savara has disclosed $35.2M raised across 3 of its 6 known rounds.
- Where is Savara headquartered?
- Savara is headquartered in Austin, US.